BFM
EPIX

Boothbay Fund Management’s ESSA Pharma EPIX Stock Holding History

Boothbay Fund Management’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-31,599
Closed -$918K – 1918
2021
Q1 		$918K Buy
+31,599
New +$735K 0.03% 640

Other funds holding EPIX

Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Boothbay Fund Management's EPIX Position: Q2 2021 in Review

Boothbay Fund Management sold out of ESSA Pharma (EPIX) in Q2 2021, closing a stake of 31,599 shares — an estimated $918K sold.

Boothbay Fund Management first reported a position in EPIX in Q1 2021 and held it in 1 quarter. The position peaked at $918K in Q1 2021. 80 funds tracked by Wall St. Rank hold EPIX as of Q2 2021.

  • Boothbay Fund Management reported no remaining ESSA Pharma position as of Q2 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 31,599 ESSA Pharma shares in Q2 2021, an estimated $918K.
  • Boothbay Fund Management first reported a position in ESSA Pharma in Q1 2021 and held it in 1 quarter.
  • Boothbay Fund Management's ESSA Pharma position peaked at $918K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held ESSA Pharma as of Q2 2021.

Based on Boothbay Fund Management's 13F filing for Q2 2021, filed 16 Aug 2021.